drugset / Trial / NCT01367509

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

NCT01367509

Phase 1 Completed 32 enrolled Bausch Health Americas, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is evaluating the Pharmacokinetics of MNTX in healthy control subjects and in patients with mild, moderate, or severe renal impairment who do not require hemodialysis.

Timeline

Start
2004-03
Primary completion
2005-01
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified Subcutaneous